AbbVie shares took a hit Friday after costs related to the drugmaker's acquisition of Apogee Therapeutics forced a cut to its full-year profit outlook.

Second-quarter revenue jumped 10% to nearly $17 billion, beating the $16.8 billion consensus estimate among analysts polled by FactSet. AbbVie posted adjusted earnings of $3.65 a share, narrowly ahead of Wall Street's call for $3.60.

But shares fell 4.2% in premarket trading as the drugmaker trimmed its outlook to account for the acquisition of Apogee Therapeutics, which is slated to close in the third quarter.

AbbVie forecasts adjusted earnings of $13.87 to $14.07 a share, down from a prior range of $13.91 to $14.11 a share. Analysts were looking for $14.06.

AbbVie's immunology portfolio commanded the lion's share of total second-quarter revenue at $8.8 billion. Blockbuster anti-inflammatory drug Skyrizi was a standout during the quarter, bringing in $5.5 billion worldwide, up 24% from the prior year.

Revenue for Rinvoq, another major anti-inflammatory drug, jumped 25% to $2.5 billion. Meanwhile, Humira revenue continued to slide, dropping 34% to $756 million in the quarter. The drug lost key patent protections in 2023 and has steadily lost market share to biosimilars since then.

Goldman Sachs analyst Asad Haider noted ahead of the report that "narrative swings" were underway at the company. AbbVie headed into earnings "from a relatively stronger foundational base, with the investment narrative becoming increasingly anchored to the emergence of new revenue drivers," Haider wrote.

He highlighted the Apogee acquisition and heightened focus around its burgeoning immunology pipeline, with several candidates that boast higher efficacy than the drugmaker's existing blockbusters, Skyrizi and Rinvoq.